MCCORMICK FRANK — SEC Form 4 filings
SEC reporting owner CIK 1257809. 12 Form 4 filings on record with FilingPulse; latest filed 2026-06-24.
Transaction summary — filings shown
Covers all 12 filings on record, filed 2024-06-25 to 2026-06-24. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 8 legs across 4 filings — 374,000 shares, $21,669,537 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 13.
- Largest priced transaction: sale of 111,755 shares @ $65.48 ($7,317,315) in BridgeBio Pharma, Inc., filed 2025-10-31.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | Director | 10 | — | 8 legs · 374,000 sh · $21,669,537 | 11 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | Director | 2 | — | — | 2 |
Form 4 filings — MCCORMICK FRANK
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-24 | 4 | BridgeBio Pharma, Inc. (BBIO) | Grant/award (A): 3,990 @ $0 · Grant/award (A): 5,277 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | BridgeBio Oncology Therapeutics, Inc. (BBOT) | Grant/award (A): 31,675 (derivative) @ $0 | EDGAR |
| 2025-10-31 | 4 | BridgeBio Pharma, Inc. (BBIO) | Sale (S): 111,755 @ $65.48 · Sale (S): 31,116 @ $66.20 · Sale (S): 3,497 @ $67.52 · Sale (S): 8,598 @ $68.50 · Sale (S): 43,393 @ $69.24 | EDGAR |
| 2025-10-29 | 4 | BridgeBio Pharma, Inc. (BBIO) | Sale (S): 1,641 @ $65 | EDGAR |
| 2025-09-08 | 4 | BridgeBio Pharma, Inc. (BBIO) | Option exercise (M): 74,000 @ $11.92 · Sale (S): 74,000 @ $53.16 · Option exercise (M): 74,000 (derivative) @ $0 | EDGAR |
| 2025-08-28 | 4 | BridgeBio Oncology Therapeutics, Inc. (BBOT) | Grant/award (A): 91,076 (derivative) @ $0 | EDGAR |
| 2025-06-26 | 4 | BridgeBio Pharma, Inc. (BBIO) | Sale (S): 100,000 @ $44.23 | EDGAR |
| 2025-06-24 | 4 | BridgeBio Pharma, Inc. (BBIO) | Grant/award (A): 6,589 @ $0 · Grant/award (A): 8,425 (derivative) @ $0 | EDGAR |
| 2025-05-09 | 4 | BridgeBio Pharma, Inc. (BBIO) | Gift (G): 33,000 @ $0 · Gift (G): 3,000 @ $0 | EDGAR |
| 2025-01-08 | 4/A | BridgeBio Pharma, Inc. (BBIO) | Gift (G): 7,400 @ $0 | EDGAR |
| 2024-12-27 | 4 | BridgeBio Pharma, Inc. (BBIO) | Gift (G): 7,400 @ $0 | EDGAR |
| 2024-06-25 | 4 | BridgeBio Pharma, Inc. (BBIO) | Grant/award (A): 26,014 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1257809 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →